Psychopharmacology Maastricht
The psychopharmacology department at Maastricht University focuses on the cognitive, behavioral, and biological effects of various substances, ranging from pharmaceutical to recreational drugs.
Learn More
Mind Altering Conversations with Mauro Cavara, featuring Steven Fülle
Check out the FIRST episode of our podcast series, MIND ALTERING CONVERSATIONS! In this series, psychedelic science student Steven Fülle talks to Dr. Mauro Cavara about his research into psilocybin being used for pain management in fibromyalgia.
Watch it here!
Congratulations to the NEW Dr. Eline C. H. M. Haijen!
After successfully defending her PhD thesis entitled: “Exploring the Adult ADHD Treatment Landscape: From Current Practices to Psychedelic Microdosing and Novel Screening Approaches.” In her thesis, she looks at novel approaches of treating ADHD with LSD microdosing.
Watch the defense here!Congratulations to the NEW Dr. Elisabeth Prevete!
On successfully defending her PhD thesis ‘Mental Effects and Potential Therapeutic Use of Kratom/Mitragynine!’ This project was a joint venture between Maastricht University and Sapienza University of Rome. This is Elisabeth’s SECOND doctorate, she now holds an MD and a PhD! Congrats once again Elisbath on a great accomplishment!
Watch the defense here!
Meet our Department!
The scientists in our lab come from many countries and backgrounds, all with highly unique research abilities. Come meet the people that make up the Psychopharmacology Department.
Learn MoreParticipate in our studies!
We're always conducting research in our department and we're frequently looking for participants to be a part of science! If you're interested, look at the studies that we are currently conducting.
View All Studies
Our Scientists
Dr. Johannes Reckweg
5-MeO-DMT, Neuropsychopharmacology, Therapy
I am Johannes, a PhD from Germany. After receiving my Bachelor’s degree from the Rijksuniversiteit Groningen, I came to Maastricht for my Master in Neuropsychology.
Dr. Malin Vedøy Uthaug
5-MeO-DMT, Consciousness, Ayahuasca
I am an altered states of consciousness researcher from Norway and one of the world leading experts on 5-MeO-DMT.
Iva Totomanova, MSc
My primary research interest lies in exploring the potential of psychedelics to be used as novel treatment options for a range of psychiatric disorders.
Dr. Rudy Schreiber
CNS Drug Discovery, Research Domain Criteria
I started my career in central nervous system drug discovery in 1993 and subsequently progressed from bench scientist to senior leadership roles at global pharmaceutical companies
Max Kaiser , MSc
I investigate whether inaccessible memories can be recovered and made retrievable again using various forms of non-invasive stimulation.
Dr. C. Rob Markus
I became an expert on the relation between stress, brain (gene) vulnerability and the development of cognitive-affective complaints/disorders as well as in testing (claims about) dietary treatment/assessment methods.
Katharina Lege, MSc
Cannabinoids, Neuroimaging, Consciousness
Coming from a background of psychology and clinical neuroscience, I developed a strong interest in altered states of the mind as in mediation or yoga practices.
Dr. Conny Quaedflieg
Intentional Forgetting, EEG, Stress Resilience
Through my extensive research experience, I have built expertise in various disciplines (psychology, psychophysiology, neurosciences) and I have become enthusiastic about bridging them.
Sarah Roche, MSc
Sustainability, Psilocybin, Environment
My PhD research focuses on psychedelic drugs as a tool to investigate the cognitive mechanisms underlying changes in sustainable behavior.
Psychedelic Research
Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study
→
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
→
Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
→
Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach
→
Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions
retinofugal, tripping, hallucinations, visual, Psychedelics, vision
→
Cannabis Research
Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users
Cognition, Psychomotor, Cannabis
→
Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans
→
Cognition and motor control as a function of 9-THC concentration in serum and oral fluid: Limits of impairment
→
Get in Touch
We are always up for communicating with people that have interesting ideas or questions. If you want to contact our department, please reach out using this form below.